Ozempic, the diabetes and weight-loss medication manufactured by Novo Nordisk, is at the center of a rapidly expanding mass tort involving more than 3,500 lawsuits alleging that the drug causes severe gastrointestinal complications, including gastroparesis (stomach paralysis). As of April 2026, 3,546 personal injury lawsuits have been filed in federal court specifically for gastroparesis, ileus, and intestinal obstruction linked to GLP-1 receptor agonists like Ozempic and Wegovy. The litigation has been consolidated into MDL 3094 in the Eastern District of Pennsylvania under Judge Karen S. Marston, where plaintiffs allege that Novo Nordisk failed to adequately warn patients and physicians about these severe risks despite evidence that the company knew of the danger.
The scope of injury has grown dramatically in recent months, with over 100 new lawsuits filed in February 2026 alone, following a high-profile wrongful death case brought in March 2026. That case involves a 76-year-old woman who died from stomach paralysis after taking Ozempic for just six months—a stark illustration of how serious these complications can become. The litigation marks a critical moment in pharmaceutical accountability, as courts are now requiring objective medical evidence to prove gastroparesis claims, moving away from subjective symptom reporting. No global settlements have been announced as of April 2026, but trials are expected to begin in late 2026 or early 2027, with estimated settlement ranges between $400,000 and $700,000 for standard cases, and potentially $350,000 to $1,000,000 or more for severe injuries including wrongful death.
Table of Contents
- What Is Gastroparesis and How Does Ozempic Cause Stomach Paralysis?
- The Master Complaint and Core Allegations in the MDL
- The Scope of Litigation and Who Is Filing Suit
- Medical Testing Requirements and Evidentiary Challenges
- Settlement Negotiations and Expected Trial Timeline
- The Role of Gastric Motility Disorders in GLP-1 Drug Mechanism
- The Future of GLP-1 Litigation and Regulatory Implications
What Is Gastroparesis and How Does Ozempic Cause Stomach Paralysis?
Gastroparesis is a medical condition in which the stomach muscles become partially or completely paralyzed, preventing normal food digestion and stomach emptying. Patients with gastroparesis experience severe nausea, early fullness after eating small amounts, abdominal pain, and vomiting—symptoms that can be debilitating and often require hospitalization. GLP-1 receptor agonists like Ozempic work by slowing gastric emptying as part of their mechanism for weight loss and blood sugar control, but this intended side effect can progress to pathological stomach paralysis in some patients.
The key distinction is that Ozempic-related gastroparesis is not reversible upon stopping the medication in all cases. Some patients continue to experience stomach paralysis weeks or months after discontinuing the drug, requiring aggressive medical intervention including nasogastric tube placement or surgical procedures. A 2025 clinical report documented a case of a 58-year-old patient who developed complete gastroparesis after four months on Ozempic and required surgical gastric stimulation implantation after the condition did not resolve following drug discontinuation. This permanent or long-lasting nature of Ozempic-induced gastroparesis distinguishes it from simple nausea or mild digestive upset that resolves quickly.
The Master Complaint and Core Allegations in the MDL
The master complaint filed in MDL 3094 on November 12, 2025, alleges that Novo Nordisk engaged in aggressive marketing of Ozempic and its sister product Wegovy for weight loss while deliberately concealing or minimizing the known risk of severe gastrointestinal complications. The complaint asserts that the company’s labeling and warnings were inadequate, failing to convey the true incidence and severity of gastroparesis, ileus (complete intestinal paralysis), and other GI injuries. The allegations include breach of warranty, failure to warn, and state law negligence claims. Plaintiff attorneys argue that internal Novo Nordisk documents show the company was aware of gastroparesis cases but prioritized marketing the drug’s weight-loss benefits over patient safety communication.
A critical limitation in these claims is that they must now overcome a stringent evidentiary standard established by Judge Marston in late 2025. The judge has ruled that plaintiffs can no longer rely solely on subjective symptoms like nausea and early satiety to prove gastroparesis—they must provide objective medical evidence from a Gastric Emptying Study (also called scintigraphy), in which a patient eats a radioactive-tagged meal and medical imaging tracks how quickly the stomach empties. This gold standard diagnostic test has substantially raised the bar for claims and may eliminate weak cases from moving forward. Plaintiffs without documented gastric emptying studies showing delayed or absent stomach emptying now face the real possibility that their claims will be dismissed.
The Scope of Litigation and Who Is Filing Suit
The litigation encompasses not only Ozempic but the broader GLP-1 drug class, with 3,363 general GLP-1 drug injury lawsuits pending in MDL 3094 as of April 2026. However, gastroparesis claims dominate the docket, representing 75 percent of all lawsuits filed. The remaining claims are distributed among ileus cases (18 percent), gallbladder complications (8 percent), and other gastrointestinal conditions (8 percent).
This breakdown reflects the documented medical literature showing that GLP-1 receptor agonists carry the highest risk for severe gastric dysfunction rather than other organ system injuries. Plaintiffs in these lawsuits include patients who took Ozempic for diabetes management, individuals who used Wegovy or Ozempic off-label for weight loss, and in the most severe cases, families of patients who died from complications of gastroparesis-related malnutrition and dehydration. The March 2026 wrongful death case is likely to serve as a bellwether for other death claims in the litigation. Families bringing these claims face a difficult emotional and legal burden: proving not only that the drug caused gastroparesis, but that the resulting condition was directly and proximately responsible for the patient’s death—a higher causation threshold than injury claims alone.
Medical Testing Requirements and Evidentiary Challenges
The shift to requiring objective gastric emptying studies represents a fundamental change in how gastroparesis claims are evaluated. Prior to the late 2025 ruling, plaintiffs could describe symptoms of nausea, vomiting, and early satiety, and some cases proceeded based on clinical diagnosis without imaging confirmation. Now, the gold standard scintigraphy test—in which a patient consumes a meal tagged with a radioactive tracer and imaging follows stomach emptying over two to four hours—must show delayed or absent emptying to establish the medical diagnosis. Importantly, this test is expensive, typically costing $1,500 to $2,500 out of pocket for uninsured patients, and some patients who suffered acute gastroparesis years ago may no longer have access to scintigraphy results if their medical records were not preserved.
This evidentiary requirement creates a tradeoff: it protects the litigation from frivolous or weak claims but may also exclude legitimate plaintiffs who experienced real gastroparesis but lack documented proof through scintigraphy. Patients who experienced severe symptoms and recovered after stopping Ozempic may not have pursued formal testing, or their primary care physicians may have diagnosed gastroparesis clinically without ordering imaging. The rule thus benefits Novo Nordisk’s defense by raising the burden of proof on plaintiffs while reducing the total claim population. For patients currently in the litigation with documented scintigraphy showing delayed gastric emptying, however, the evidentiary standard strengthens their claims by removing the subjectivity of symptom-based diagnosis.
Settlement Negotiations and Expected Trial Timeline
As of April 2026, no global settlement agreement has been announced between plaintiff counsel and Novo Nordisk, despite ongoing settlement discussions. The lack of a mass settlement offer suggests either that Novo Nordisk is contesting the scientific and medical causation evidence, or that the parties remain far apart on valuation and the scope of a potential settlement class. Given the complexity of individual causation issues—each patient must prove both that Ozempic caused their gastroparesis and that their specific case meets the evidentiary standards—a single global settlement encompassing all 3,546 cases may be impractical. Instead, the litigation is expected to proceed to individual trials or smaller settlement clusters, with the first bellwether trials anticipated in late 2026 or early 2027.
Settlement valuation estimates for standard gastroparesis cases range from $400,000 to $700,000, reflecting the serious nature of the injury, ongoing medical management costs, and pain and suffering. Cases involving more severe injuries—such as patients who required surgical intervention, experienced permanent disability, or whose family member died—are estimated to settle or award between $350,000 and $1,000,000 or more. A warning to potential claimants: these are estimates based on comparable pharmaceutical litigation and have not been established by any actual settlement agreement. Actual settlement values may be substantially lower or higher depending on trial outcomes, judge and jury responses, and Novo Nordisk’s willingness to resolve the litigation. Delays in the trial schedule, appeals, or changes in judicial assignments could extend the litigation timeline by years.
The Role of Gastric Motility Disorders in GLP-1 Drug Mechanism
GLP-1 receptor agonists were originally designed to treat type 2 diabetes by stimulating insulin secretion and slowing gastric emptying, the latter of which helps patients feel fuller longer and eat smaller portions. When used at the low doses prescribed for diabetes management (0.5 to 1.8 mg per week for Ozempic), the delayed gastric emptying is generally tolerable and expected. However, weight-loss formulations like Wegovy are prescribed at higher doses (up to 2.4 mg per week), and off-label use of Ozempic for weight loss often involves patients taking higher doses than prescribed for diabetes.
At these elevated doses, the inhibition of gastric muscle contraction can cross from intentional to pathological, resulting in gastroparesis that does not resolve when the dose is lowered or the medication is stopped. A specific example illustrates this distinction: A 42-year-old patient prescribed Ozempic 0.5 mg weekly for type 2 diabetes experienced mild nausea and early fullness—expected GLP-1 side effects—but these resolved within a few weeks as her body adapted. In contrast, a 39-year-old woman who obtained Ozempic off-label for weight loss and self-escalated to 2 mg weekly developed severe vomiting and inability to consume solid food, and even after stopping the medication, her stomach remained paralyzed and she required hospitalization and nasogastric tube feeding. The difference in dosing and context matters critically for both medical management and for determining whether a case has sufficient medical causation to proceed in litigation.
The Future of GLP-1 Litigation and Regulatory Implications
The Ozempic gastroparesis MDL is the first major wave of GLP-1 drug injury litigation, but it may not be the last. Additional claims involving other GLP-1 drugs such as Mounjaro (tirzepatide), Saxenda, and newer formulations continue to emerge, suggesting that the liability exposure extends across the entire drug class. Regulatory agencies including the FDA have begun reviewing adverse event reports linking GLP-1 drugs to severe gastrointestinal complications, and there is growing discussion within the medical community about whether drug labeling should be revised to provide clearer warnings about the risk of permanent or long-lasting gastroparesis.
The outcomes of trials in MDL 3094—particularly the verdicts in early bellwether cases and the resolution of the wrongful death claim—will likely influence how future GLP-1 litigation proceeds and whether manufacturers update their warnings and marketing materials. Looking forward to late 2026 and 2027, the litigation will reach a critical juncture as the first trials occur and initial settlement data becomes available. These outcomes will establish precedent for valuation, causation standards, and the strength of Novo Nordisk’s defenses. Patients who believe they have suffered Ozempic-related gastroparesis should act promptly to preserve medical records, gather any scintigraphy or other objective imaging, and consult with an attorney experienced in pharmaceutical litigation—the evidentiary requirements are now strict, and documentation matters significantly.